OakChart

Incannex Healthcare Inc

IXHLHealthcare·Drug Manufacturers - Specialty & Generic·Australia·Nano·NASD·Nov 11 • 10:59 AM ET

2.09+0.08 (3.73%)
2026-11-11 17:00 CET
Market cap
25.21 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-19.30 USD m
Free cash flow, TTM
-13.48 USD m
EPS diluted, TTM
-1.68
P/E
-
Compare

Price

IXHL against its 20, 50 and 200-day averages
2050200earnings
2.004.006.008.0010.00431K861KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IXHLclose 2.0920-day 2.5250-day 2.98200-day 3.872.09

86.0% under the 52-week high of 14.91 on 4 Dec 2025. 52-week low 1.96 on 10 Nov 2026. Last 15 sessions, 42.3% high to low

Profile

IXHL
52-week range, 1% of the way up
1.9614.91

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Employees12
IPOMar 02, 2022
Beta2.86
ATR, 14d0.18
Rel volume0.70
Short float3.23%
Insider own11.60%
Inst own4.84%

Snapshot

6 groups

Valuation

Index-
Market Cap26.15M
Enterprise Value-41.46M
Income-19.30M
Sales0.00M
Book/sh5.37
Cash/sh5.40
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees12
IPOMar 02, 2022

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.39
P/C0.39
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio48.81
Current Ratio48.81
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.68
EPS next Y-2.23
EPS next Q-0.51
EPS this Y-29.41%
EPS next Y-6.94%
EPS next 5Y-7.39%
EPS past 3/5Y-16.41% -9.71%
Sales past 3/5Y- -
EPS Y/Y TTM95.90%
Sales Y/Y TTM-100.00%
EPS Q/Q98.80%
Sales Q/Q-
EarningsSep 02
EPS/Sales Surpr.0.00% -

Ownership

Insider Own11.60%
Insider Trans0.00%
Inst Own4.84%
Inst Trans-5.81%
ROA-41.32%
ROE-47.80%
ROIC-28.64%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-17.29%
SMA50-29.94%
SMA200-46.09%
Trades-

Technical

Shs Outstand12.54M
Shs Float11.09M
Short Float3.23%
Short Ratio4.24
Short Interest0.36M
52W High14.91 -86.02%
52W Low1.96 6.38%
Volatility10.28% 6.91%
ATR (14)0.18
RSI (14)26.17
Beta2.86
Rel Volume0.70
Avg Volume84.46K
Volume15,866

Performance

Perf Week-16.27%
Perf Month-28.35%
Perf Quarter-34.02%
Perf Half Y-45.84%
Perf YTD-80.59%
Perf Year-80.69%
Perf 3Y-98.44%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price18.61
Prev Close2.01
Price2.09
Change %3.73%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Jun 08, 2026InitiatedAAlliance Global PartnersBuy$18+763.3%

Peers

Mkt cap
TickerCompanyMkt cap
MTRIMentari Therapeutics Inc7.58M
CMPSCompass Pathways Plc ADR1.33B
OPTHOptimi Health Corp13.26M
ENVBEnveric Biosciences Inc6.83M
CMNDClearmind Medicine Inc2.79M
VVOSVivos Therapeutics Inc2.91M
INSPInspire Medical Systems Inc1.78B
ARTLArtelo Biosciences Inc1.20M
SKYESkye Bioscience Inc3.75M
JAZZJazz Pharmaceuticals plc15.77B

Held by

AUM
TickerCompanyAUM
PSILAdvisorShares Psychedelics ETFAUM: 43.26M

News

latest 14 of 206
  • Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26 (Newsfile)
  • Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position (GlobeNewswire)
  • Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X (GlobeNewswire)
  • Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026 (GlobeNewswire)
  • Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea (GlobeNewswire)
  • Loading…
  • Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea (GlobeNewswire)
  • Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility (GlobeNewswire) +6.54%
  • Incannex Announces Initiation of Research Coverage by Alliance Global Partners (GlobeNewswire) +7.94%
  • Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea (GlobeNewswire)
  • Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development (GlobeNewswire) -13.91%
  • Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness (GlobeNewswire) +8.49%
  • Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position (GlobeNewswire)
  • Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research (GlobeNewswire) +15.83%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q42026-09-02-0.120-0.120-0.2000.000.001
2026Q32026-05-14-0.335-0.600-0.3140.00-1
2026Q22026-02-13-0.600-0.600-0.5600.00-1
2026Q12025-11-13-0.600-11.700-0.6200.200.201
2025Q42025-08-27-56.700-8.700-15.6870.200.201
2025Q32025-05-15-6.000-13.800-6.0630.100.101
2025Q22025-02-14-9.900-13.200-10.0330.000.101
2025Q12024-11-14-8.700-14.700-9.2160.07-1
2024Q42024-09-30-11.700--12.2110.00--
2023S12023-02-27-3.078-----
2027Q1---0.510--0.002
2027Q2---0.515--0.002
2027Q3---0.535--0.002
2027Q4---0.535--0.002
2028Q1---0.690---1
2028Q2---0.690---1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2012FY-61.680--0.00-
2013FY-230.45--0.15-
2014FY-192.17--192.380.02-
2022FY-6.282-4.236-1.0890.530.59
2023FY-6.333-27.762-1.0490.890.06
2024FY-34.500--34.2590.01-
2025FY-40.500-28.800-1.6900.090.20
2026FY-1.615-1.565-1.6900.000.00
2027FY--2.090--0.00
2028FY--2.235--0.00
2029FY--2.000--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2027Q1S2026-09-291000.000.000.00
2027Q1E2026-09-30201-0.51-0.66-0.36
2027Q1E2026-09-29100-0.36-0.36-0.36
2027Q1E2026-09-13100-0.01-0.01-0.01
2027Q1E2026-09-02200-0.19-0.36-0.01
2027Q1E2026-08-29200-0.19-0.36-0.01
2027Q1E2026-06-15210-0.19-0.36-0.01
2027Q1E2026-06-04100-0.36-0.36-0.36
2027Q1E2026-05-14100-0.30-0.30-0.30
2027Q1E2026-02-13100-0.30-0.30-0.30
2027Q1E2025-11-19100-0.30-0.30-0.30
2027FYS2026-09-021000.000.000.00
2027FYS2026-06-041000.000.000.00
2027FYS2025-11-1910040.0040.0040.00

Estimate history

EPS, annual-1.101-0.522-0.553-1.042-1.089-1.049-34.259-40.824-1.656
Period201820192020202120222023202420252026
EPS, quarterly-12.211-9.216-10.033-6.063-15.687-0.62-0.56-0.314-0.188
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Sales, annual0.78400.4881.442000.0120.0860
Period201820192020202120222023202420252026
Sales, quarterly0.0120.0740.012000000
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Shares, annual2.6374.8496.2398.90310.76913.2250.5296.47912.544
Period201820192020202120222023202420252026
Shares, quarterly0.5290.5880.5930.5936.47911.5911.97413.68312.544
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.090.010.000.001.440.490.00
Cost of Goods Sold Incl. D&A0.240.240.250.100.090.002.090.650.03
Gross Profit-0.24-0.24-0.16-0.09-0.090.00-0.65-0.16-0.03
Selling, General and Administrative Excl. Other22.7922.7923.6329.9514.2811.387.862.530.93
Research and Development5.215.2110.7512.886.303.903.54--
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-23.03-23.03-23.79-30.04-14.37-11.38-8.51-2.70-0.96
Interest Expense0.000.000.300.00-0.000.000.000.06
Unusual Expense0.900.6223.100.000.000.000.000.000.00
Net Income Before Taxes-23.96-23.96-48.64-29.86-14.12-11.38-8.48-2.63-1.02
Income Taxes-4.66-4.66-1.76-11.40-0.68-0.570.000.000.00
Consolidated Net Income-19.30-19.30-46.89-18.46-13.44-10.81-8.48-2.63-1.02
Net Income From Continuing Operations-19.30-19.30-46.89-18.46-13.44-10.81-8.48-2.63-1.02
Net Income-19.30-19.30-46.89-18.46-13.44-10.81-8.48-3.15-1.94
EPS (Recurring)-1.41-1.62-26.75-34.26-1.05-1.09-1.04-0.55-0.52
EPS (Basic, Before Extraordinaries)-1.68-1.66-40.82-34.26-1.05-1.09-1.04-0.55-0.52
EPS (Diluted)-1.68-1.66-40.82-34.26-1.05-1.09-1.04-0.55-0.52
EBITDA-22.79-22.79-23.54-29.94-14.28-11.38-8.51-2.67-0.93
Non-Operating Income (Expense)-0.03-0.31-1.450.180.240.000.030.060.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.567.562.617.052.151.060.450.270.02
Price To Sales Ratio--86.423,960.26-----
Gross Margin---186.05-758.33---45.28-33.80-
Operating Margin---27,661.63-250,341.67---590.38-552.65-
Net Margin---54,517.44-153,825.00---588.30-645.27-
Shares Outstanding12.5412.546.480.5313.2310.778.906.244.85
Market Capitalization25.2125.211,048.191,166.673,967.533,967.52---

Income statement, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q32025Q22025Q1
Total Revenue0.000.000.000.000.000.000.010.07
Cost of Goods Sold Incl. D&A0.050.070.060.070.060.000.120.07
Gross Profit-0.05-0.07-0.06-0.07-0.060.00-0.110.01
Selling, General and Administrative Excl. Other5.143.986.946.737.475.004.896.26
Research and Development1.490.322.281.123.702.741.412.90
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.19-4.05-7.00-6.79-7.53-5.00-5.00-6.25
Interest Expense0.000.000.000.00-0.130.170.00
Unusual Expense1.00-0.100.000.0023.65-0.700.280.00
Net Income Before Taxes-6.20-3.97-7.00-6.80-31.17-4.39-6.85-6.23
Income Taxes-3.71-0.08-0.48-0.390.43-0.42-0.96-0.81
Consolidated Net Income-2.49-3.88-6.52-6.41-31.60-3.97-5.89-5.42
Net Income From Continuing Operations-2.49-3.88-6.52-6.41-31.60-3.97-5.89-5.42
Net Income-2.49-3.88-6.52-6.41-31.60-3.97-5.89-5.42
EPS (Recurring)-0.13-0.32-0.56-0.62-7.47-6.81-9.70-9.22
EPS (Basic, Before Extraordinaries)-0.19-0.31-0.56-0.62-15.69-6.06-10.03-9.22
EPS (Diluted)-0.19-0.31-0.56-0.62-15.69-6.06-10.03-9.22
EBITDA-5.14-3.98-6.94-6.73-7.47-5.01-4.88-6.19
Non-Operating Income (Expense)-0.01-0.01-0.01-0.000.000.05-1.390.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.191.472.282.631.300.330.440.36
Price To Sales Ratio---12,006.40151.58135.52381.26408.25
Gross Margin-------931.8010.56
Operating Margin-------41,700.00-8,451.35
Net Margin-------49,116.67-7,324.32
Shares Outstanding12.5413.6811.9711.596.480.590.590.59
Market Capitalization25.2134.62128.60161.441,048.19300.79942.62877.73

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments67.7115.045.8622.2125.796.852.480.070.19
Short Term Receivables4.824.6310.020.190.200.130.280.080.04
Inventories0.000.000.000.000.000.000.130.110.16
Other Current Assets0.300.300.330.690.060.030.020.020.00
Total Current Assets72.8319.9616.2023.0926.057.002.920.270.40
Net Property, Plant & Equipment0.100.490.850.790.000.000.000.060.07
Total Investments and Advances0.050.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.0035.090.000.000.000.030.05
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets72.9820.4517.0558.9726.057.002.920.360.52
Short Term Debt Incl. Current Port. of LT Debt0.060.180.160.110.000.000.000.050.26
Accounts Payable1.136.070.531.800.890.180.410.260.37
Other Current Liabilities0.300.734.930.640.490.390.330.350.18
Total Current Liabilities1.496.985.622.561.380.570.740.660.81
Long Term Debt0.030.070.210.410.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Other Liabilities4.080.000.000.000.000.000.000.000.00
Total Liabilities5.617.065.832.971.380.570.740.660.81
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity67.3713.3911.2256.0024.676.442.18-0.29-0.28
Total Shareholders Equity67.3713.3911.2256.0024.676.442.18-0.29-0.28
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity67.3713.3911.2256.0024.676.442.18-0.29-0.28
Total Liabilities & Stockholders Equity72.9820.4517.0558.9726.057.002.920.360.52
Book Value Per Share5.372.0721.204.232.290.720.35-0.06-0.11
Tangible Book Value Per Share5.372.0721.201.582.290.720.35-0.07-0.13
Full-Time Employees1212910533--
Price to Book Ratio0.3778.2982.5270.8562.29----
Return on Assets-41.32-250.09-48.57-31.62-65.41-170.98-160.62-230.17-354.07
Return on Equity-47.80-381.09-54.92-33.32-69.51-196.87-279.34--
Return on Invested Capital-28.64-348.25-161.54-23.83-43.82-131.76-144.54--
Quick Ratio48.812.862.889.0218.8412.363.780.250.29
Current Ratio48.812.862.889.0218.8412.363.950.410.49

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-20.21-19.30-46.89-18.46-13.44-10.81-8.48-3.15-1.94
Depreciation0.250.240.250.100.09-0.000.020.03
Other Funds (Non Cash)8.628.2327.358.962.140.633.320.440.51
Funds from Operations-11.34-10.83-19.29-9.40-11.21-10.18-5.16-2.68-1.40
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-2.13-2.046.78-6.450.480.890.000.06-0.14
Cash from Operating Activities-13.47-12.87-12.51-15.85-10.72-9.29-5.15-2.62-1.55
Capital Expenditures-0.01-0.01-0.01-0.28-0.320.000.000.00-0.02
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.020.010.00
Purchase or Sale of Investments-0.09-0.080.000.000.000.000.000.000.00
Purchase of Investments-0.09-0.080.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.10-0.09-0.01-0.28-0.320.000.020.01-0.02
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock69.0065.9047.470.008.2929.879.255.011.56
Repurchase of Common Pref Stock-9.84-9.400.000.000.000.000.000.000.00
Sale of Common Pref Stock78.8475.3047.470.008.2929.879.255.011.56
Proceedsfrom Stock Options78.8475.3047.470.008.2929.879.255.011.56
Issuance or Reduction of Debt, Net0.000.00-1.310.000.000.000.00-0.04-0.10
Change in Long Term Debt0.000.00-1.130.000.000.000.000.000.00
Issuance of Long Term Debt0.000.002.670.000.000.000.000.000.00
Reduction of Long Term Debt0.000.00-3.800.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-24.770.000.000.000.000.000.00
Other Financing Activities Uses0.000.00-24.770.000.000.000.000.000.00
Cash from Financing Activities69.0065.9021.400.008.2629.879.254.961.47
Exchange Rate Effect-0.28-0.270.31-0.14-----
Net Change in Cash55.1552.679.18-16.26-2.7920.584.122.35-0.10
Free Cash Flow-13.48-12.88-12.52-16.12-11.05-9.29-5.15-2.62-1.56
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Cash & Short Term Investments67.7174.4569.1973.2815.048.11
Short Term Receivables4.825.465.304.764.637.34
Inventories0.000.000.000.000.000.00
Other Current Assets0.300.180.190.260.300.18
Total Current Assets72.8380.1074.6878.3019.9615.63
Net Property, Plant & Equipment0.100.160.270.380.490.57
Total Investments and Advances0.050.030.060.050.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets72.9880.2875.0178.7220.4516.20
Short Term Debt Incl. Current Port. of LT Debt0.060.070.110.150.181.58
Accounts Payable1.131.601.231.276.071.04
Other Current Liabilities0.300.250.210.240.734.75
Total Current Liabilities1.491.931.551.656.987.37
Long Term Debt0.030.040.050.060.070.10
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities4.083.080.000.000.001.32
Total Liabilities5.615.051.601.717.068.79
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity67.3775.2373.4177.0113.397.40
Total Shareholders Equity67.3775.2373.4177.0113.397.40
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity67.3775.2373.4177.0113.397.40
Total Liabilities & Stockholders Equity72.9880.2875.0178.7220.4516.20
Book Value Per Share5.375.506.136.642.0712.49
Tangible Book Value Per Share5.375.506.136.642.0712.49
Full-Time Employees12---12-
Price to Book Ratio0.370.491.752.1078.2940.63
Return on Assets-41.32-100.36-112.64-101.03-250.09-130.01
Return on Equity-47.80-117.17-130.42-114.52-381.09-201.88
Return on Invested Capital-3.70-5.16-8.88-8.31-234.74-52.86
Quick Ratio48.8141.5648.2747.512.862.12
Current Ratio48.8141.5648.2747.512.862.12

Cash flow, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Net Income-2.71-4.55-6.54-6.41-31.63-3.60
Depreciation0.050.070.060.070.06-0.01
Other Funds (Non Cash)2.371.302.312.6424.65-0.27
Funds from Operations-0.29-3.17-4.17-3.70-6.92-3.87
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital3.720.08-0.47-5.463.840.97
Cash from Operating Activities3.43-3.09-4.65-9.16-3.08-2.90
Capital Expenditures0.00-0.01-0.00-0.00-0.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-0.03-0.02-0.00-0.040.000.00
Purchase of Investments-0.03-0.02-0.00-0.040.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.03-0.02-0.00-0.04-0.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-7.087.851.0567.1835.6711.30
Repurchase of Common Pref Stock-7.43-1.23-1.180.000.000.00
Sale of Common Pref Stock0.349.092.2367.1835.6711.30
Proceedsfrom Stock Options0.349.092.2367.1835.6711.30
Issuance or Reduction of Debt, Net0.000.000.000.00-0.15-3.77
Change in Long Term Debt0.000.000.000.000.01-3.76
Issuance of Long Term Debt0.000.000.000.000.06-0.06
Reduction of Long Term Debt0.000.000.000.00-0.05-3.70
Net Financing Active Other Cash Flow0.30-0.300.000.00-24.39-0.12
Other Financing Activities Uses0.30-0.300.000.00-24.39-0.12
Cash from Financing Activities-6.797.561.0567.1811.137.41
Exchange Rate Effect-3.303.14-0.390.270.210.03
Net Change in Cash-6.697.58-3.9958.248.264.53
Free Cash Flow3.43-3.10-4.65-9.16-3.08-2.90

Revenue breakdown

Pharmaceutical Preparations2025: 86.00K
Australia2025: 86.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.23%0.4M11.1M83.28K
2026-10-153.71%0.4M11.1M88.84K
2026-09-304.14%0.5M11.0M122.88K
2026-09-156.82%0.7M10.5M147.77K
2026-08-317.00%0.7M10.5M196.20K
2026-08-147.73%0.8M10.5M216.96K
2026-07-318.42%0.9M10.5M250.15K
2026-07-158.48%1.0M11.9M330.97K
2026-06-300.15%0.5M343.0M364.55K
2026-06-150.22%0.8M343.0M412.71K
2026-05-290.24%0.8M343.5M511.39K
2026-05-150.23%0.8M343.5M552.45K
2026-04-300.29%1.0M343.0M539.74K
2026-04-157.94%0.9M11.4M493.22K
2026-03-31-0.8M-454.53K
2026-03-13-1.3M-425.08K
2026-02-27-0.8M-485.18K
2026-02-136.36%0.7M11.4M462.13K
2026-01-306.33%0.7M11.4M502.40K
2026-01-154.87%0.6M11.4M633.50K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.000.104.900.000.0000.000.000.932-0.0090.000
call2.000.004.600.000.0000.000.000.620-0.0180.001
call3.000.001.000.000.0000.000.000.0000.0000.000
call4.000.004.900.0010.8260.000.000.684-0.0700.001
call5.000.004.900.0011.7350.000.000.675-0.0760.001
call6.000.004.900.0012.2290.000.000.664-0.0810.001
call7.000.004.900.0012.8300.000.000.661-0.0850.001
put1.000.000.050.003.6690.000.00-0.072-0.0080.000
put2.000.000.300.250.0003510.000.0000.0000.000
put3.000.004.900.000.0000.000.00-0.297-0.0610.001
put4.000.105.000.000.0000.000.00-0.313-0.0700.001
put5.000.505.400.000.0000.000.00-0.324-0.0760.001
put6.001.506.400.000.0000.000.00-0.335-0.0810.001
put7.002.507.500.000.0000.000.00-0.338-0.0840.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-28ARSAnnual report to security holders. 2026-06-30SEC
2026-10-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-12-17SEC
2026-09-2510-KAnnual report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-08-258-KCurrent report2026-08-25SEC
2026-08-14SCHEDULE 13GSEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-238-KCurrent report2026-07-23SEC
2026-06-258-KCurrent report2026-06-25SEC
2026-06-108-KCurrent report2026-06-10SEC
2026-06-098-KCurrent report2026-06-09SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-04-228-KCurrent report2026-04-22SEC
2026-03-278-KCurrent report2026-03-27SEC
2026-03-258-KCurrent report2026-03-25SEC
2026-03-188-KCurrent report2026-03-18SEC
2026-03-178-KCurrent report2026-03-16SEC
2026-03-12424B5SEC
2026-03-128-KCurrent report2026-03-12SEC
2026-03-128-KCurrent report2026-03-11SEC
2026-02-258-KCurrent report2026-02-24SEC
2026-02-1310-QQuarterly report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-01-298-KCurrent report2026-01-29SEC
2026-01-228-KCurrent report2026-01-22SEC
2026-01-168-KCurrent report2026-01-15SEC
2026-01-158-KCurrent report2026-01-15SEC
2026-01-148-KCurrent report2026-01-14SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
AdvisorShares Investments LLC1.34%
LPL Financial LLC1.22%
COMMONWEALTH EQUITY SERVICES, LLC0.11%
MILLENNIUM MANAGEMENT LLC0.03%
JANE STREET GROUP, LLC0.02%
UBS Group AG0.02%
Quent Capital, LLC0.02%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.01%
BARCLAYS PLC0.01%
CITADEL ADVISORS LLC0.00%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.07%
AdvisorShares Psychedelics ETF0.02%
Victory Extended Market Index Fund0.00%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. IXHL. Cached 15 minutes.

Some panels did not load: insider.